SLC47A2

Multidrug and toxin extrusion protein 2 · Q86VL8 · SLC47A2 on Sugi Atlas →

18,474 patent compounds predicted against SLC47A2, 14,531 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Famotidine (SCHEMBL973)	1.00	2/20
Famotidine (SCHEMBL39237)	1.00	2/20
Famotidine (SCHEMBL458654)	1.00	2/20
Famotidine (SCHEMBL1863201)	0.98	2/20
Famotidine (SCHEMBL1863206)	0.95	2/20
Irinotecan (SCHEMBL478241)	0.84	2/20
Irinotecan (SCHEMBL1408971)	0.78	2/20
Famotidine (SCHEMBL1230949)	0.75	2/20
Famotidine (SCHEMBL188452)	0.67	2/20
Famotidine (SCHEMBL453397)	0.62	2/20
Maleic Acid (SCHEMBL1648905)	0.58	2/20
Ebrotidine (SCHEMBL1649379)	0.50	2/20
Tiotidine (SCHEMBL118501)	0.47	2/20
SCHEMBL1339650	0.39	2/20
Pentamidine (SCHEMBL3329)	1.00	1/20
Dabigatran (SCHEMBL3573)	1.00	1/20
Topotecan (SCHEMBL3836)	1.00	1/20
Irinotecan (SCHEMBL4034)	1.00	1/20
Ethinyl Estradiol (SCHEMBL4071)	1.00	1/20
Zafirlukast (SCHEMBL4175)	1.00	1/20

Clinical trials — most relevant to SLC47A2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Impact of Polymorphisms of OCT2 and OCTN1 on the Kinetic Disposition of Gabapentin in Patients Undergoing Chronic Use	PHASE4	COMPLETED
Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia	PHASE1/PHASE2	COMPLETED
The Effect of Perioperative Ketamine on Acute and Chronic Pain After Major Back Surgery	PHASE2	COMPLETED
Effect of, OAT3, on the Renal Secretion of Cefotaxime	PHASE1	COMPLETED
Drug-drug Interaction Study in Healthy Male Volunteers Following the Administration of Pantoprazole and Rosuvastatin	PHASE1	COMPLETED
Identification and Validation of Biomarkers for Breast Cancer Resistance Protein (BCRP)	PHASE1	COMPLETED
Influence of Ethnicity and ABCB1 Gene Polymorphism on the Pharmacokinetics of Azithromycin in Healthy Bangladeshi Volunteers	PHASE1	UNKNOWN
Phase I Trial of Tariquidar (XR9576) in Combination With Doxorubicin, Vinorelbine, or Docetaxel in Pediatric Patients With Solid Tumors	PHASE1	COMPLETED
Furosemide and Creatinine Tubular Stress Test in Order to Measure Proximal Tubule Residual Function	PHASE1	COMPLETED
Drug-Drug Interaction of Rifampicin and Cyclosporine on Methotrexate Pharmacokinetics in Healthy Subjects	PHASE1	ACTIVE_NOT_RECRUITING
Pharmacokinetic Drug-Drug Interaction Study to Identify Biomarkers of Kidney Transporters	EARLY_PHASE1	COMPLETED
Metformin Gastrointestinal Intolerance: Measurement of Mitochondrial Complex I	EARLY_PHASE1	COMPLETED
the Effect of ABCC2 Genetic Polymorphism on Neurotoxicity in Gastrointestinal Cancer Patients Receiving Oxaliplatin	nan	UNKNOWN
Impact of Genetics on Metformin Pharmacokinetics	nan	COMPLETED
Cancer and Hearing Loss Related in Children	nan	COMPLETED
Study of CYP2C19 and ALDH3A1 Polymorphisms in Breast Cancer Patients	nan	UNKNOWN
Impact of Polymorphisms of OAT1, OAT3, and OCT2 on Transportation of Potential Nephrotoxic Drugs	nan	COMPLETED
Natural History Study of SLC25A46 Mutation-related Mitochondriopathy	nan	COMPLETED
Study of ABCB1,SLC22A16 Drug Transporter Genes and Doxorubicin and Cyclophosphamide Toxicity in Brest Cancer Patient	nan	UNKNOWN
Bile Acid Effects in Fetal Arrhythmia Study	nan	UNKNOWN
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis	nan	RECRUITING
PET/CT Scans Using the Tracer 11C-Csar, a Bile Acid Analog, to Depict and Visualize Cholestatic Disorders in Patients with Genetic Liver Disorders and Healthy Individuals	nan	ENROLLING_BY_INVITATION
Role of the ATP7A Transporter in Ovarian Cancer	nan	COMPLETED
Collection of Tissue Samples for Study of Multidrug Resistance	nan	COMPLETED
Screening of Susceptibility Genes for APAP Induced Drug Induced LIver Injury in ChiNese Population: a Case-control Study	nan	RECRUITING
Coproporphyrine Isomers and Methotrexate Elimination	nan	COMPLETED
Pharmacogenetics Study in Taiwan's Ethnic Groups	nan	COMPLETED
Pharmacogenomic Testing to Optimize Antidepressant Drug Therapy	nan	COMPLETED
Identifying Diuretic Resistance in Patients With Acute Heart Failure	nan	COMPLETED
Incidence of Iron Deficiency in Polycythemia Vera (PV) and Association With Disease Features	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a SLC47A2 binder may also engage these)

Protein	Name	Similarity
Q5R7E4	—	0.999	Q5R7E4 →
Q8K0H1	—	0.998	Q8K0H1 →
A7KAU2	—	0.996	A7KAU2 →
Q5I0E9	—	0.996	Q5I0E9 →
Q5RFD2	—	0.995	Q5RFD2 →
A7KAU3	—	0.994	A7KAU3 →
SLC47A1	Multidrug and toxin extrusion protein 1	0.994	landscape →
Q3V050	—	0.991	Q3V050 →
A1L1P9	—	0.989	A1L1P9 →
A4IIS8	—	0.989	A4IIS8 →
F4J158	—	0.982	F4J158 →
Q8L616	—	0.981	Q8L616 →
O49660	—	0.979	O49660 →
Q9USK3	—	0.976	Q9USK3 →
F4JH46	—	0.974	F4JH46 →
O64759	—	0.973	O64759 →
A8I499	—	0.972	A8I499 →
Q9UT92	—	0.972	Q9UT92 →
Q8WUX1	—	0.972	Q8WUX1 →
Q9JJ59	—	0.971	Q9JJ59 →
Q9QYJ4	—	0.970	Q9QYJ4 →
A4IF94	—	0.970	A4IF94 →
Q503G8	—	0.970	Q503G8 →
Q8K1A5	—	0.969	Q8K1A5 →
P70187	—	0.969	P70187 →
Q9LZ20	—	0.969	Q9LZ20 →
B2RX12	—	0.969	B2RX12 →
Q9SHH0	—	0.969	Q9SHH0 →
Q9UIG8	—	0.968	Q9UIG8 →
Q99P65	—	0.968	Q99P65 →